221 related articles for article (PubMed ID: 26842595)
1. In Vitro-In Vivo Extrapolation Scaling Factors for Intestinal P-glycoprotein and Breast Cancer Resistance Protein: Part II. The Impact of Cross-Laboratory Variations of Intestinal Transporter Relative Expression Factors on Predicted Drug Disposition.
Harwood MD; Achour B; Neuhoff S; Russell MR; Carlson G; Warhurst G; Rostami-Hodjegan A
Drug Metab Dispos; 2016 Mar; 44(3):476-80. PubMed ID: 26842595
[TBL] [Abstract][Full Text] [Related]
2. In Vitro-In Vivo Extrapolation Scaling Factors for Intestinal P-Glycoprotein and Breast Cancer Resistance Protein: Part I: A Cross-Laboratory Comparison of Transporter-Protein Abundances and Relative Expression Factors in Human Intestine and Caco-2 Cells.
Harwood MD; Achour B; Neuhoff S; Russell MR; Carlson G; Warhurst G;
Drug Metab Dispos; 2016 Mar; 44(3):297-307. PubMed ID: 26631742
[TBL] [Abstract][Full Text] [Related]
3. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
Graber-Maier A; Gutmann H; Drewe J
Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289
[TBL] [Abstract][Full Text] [Related]
4. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R; Martin P; Surry D; Sharma P; Fenner K
Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
[TBL] [Abstract][Full Text] [Related]
5. Zinc finger nuclease-mediated gene knockout results in loss of transport activity for P-glycoprotein, BCRP, and MRP2 in Caco-2 cells.
Sampson KE; Brinker A; Pratt J; Venkatraman N; Xiao Y; Blasberg J; Steiner T; Bourner M; Thompson DC
Drug Metab Dispos; 2015 Feb; 43(2):199-207. PubMed ID: 25388687
[TBL] [Abstract][Full Text] [Related]
6. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
Dahan A; Amidon GL
Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
[TBL] [Abstract][Full Text] [Related]
7. The Use of Transporter Probe Drug Cocktails for the Assessment of Transporter-Based Drug-Drug Interactions in a Clinical Setting-Proposal of a Four Component Transporter Cocktail.
Ebner T; Ishiguro N; Taub ME
J Pharm Sci; 2015 Sep; 104(9):3220-8. PubMed ID: 25981193
[TBL] [Abstract][Full Text] [Related]
8. Characterization of efflux transporters involved in distribution and disposition of apixaban.
Zhang D; He K; Herbst JJ; Kolb J; Shou W; Wang L; Balimane PV; Han YH; Gan J; Frost CE; Humphreys WG
Drug Metab Dispos; 2013 Apr; 41(4):827-35. PubMed ID: 23382458
[TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
Durmus S; Xu N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharmacol Res; 2013 Oct; 76():9-16. PubMed ID: 23827160
[TBL] [Abstract][Full Text] [Related]
10. Black ginger extract and its active compound, 5,7-dimethoxyflavone, increase intestinal drug absorption via efflux drug transporter inhibitions.
Boonnop R; Meetam P; Siangjong L; Tuchinda P; Thongphasuk P; Soodvilai S; Soodvilai S
Drug Metab Pharmacokinet; 2023 Jun; 50():100500. PubMed ID: 36948091
[TBL] [Abstract][Full Text] [Related]
11. Imaging the Impact of the P-Glycoprotein (ABCB1) Function on the Brain Kinetics of Metoclopramide.
Pottier G; Marie S; Goutal S; Auvity S; Peyronneau MA; Stute S; Boisgard R; Dollé F; Buvat I; Caillé F; Tournier N
J Nucl Med; 2016 Feb; 57(2):309-14. PubMed ID: 26585058
[TBL] [Abstract][Full Text] [Related]
12. The Regional-Specific Relative and Absolute Expression of Gut Transporters in Adult Caucasians: A Meta-Analysis.
Harwood MD; Zhang M; Pathak SM; Neuhoff S
Drug Metab Dispos; 2019 Aug; 47(8):854-864. PubMed ID: 31076413
[TBL] [Abstract][Full Text] [Related]
13. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass.
Bruyère A; Declèves X; Bouzom F; Ball K; Marques C; Treton X; Pocard M; Valleur P; Bouhnik Y; Panis Y; Scherrmann JM; Mouly S
Mol Pharm; 2010 Oct; 7(5):1596-607. PubMed ID: 20604570
[TBL] [Abstract][Full Text] [Related]
14. Quantitative transporter proteomics by liquid chromatography with tandem mass spectrometry: addressing methodologic issues of plasma membrane isolation and expression-activity relationship.
Kumar V; Prasad B; Patilea G; Gupta A; Salphati L; Evers R; Hop CE; Unadkat JD
Drug Metab Dispos; 2015 Feb; 43(2):284-8. PubMed ID: 25488931
[TBL] [Abstract][Full Text] [Related]
15. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions.
Reyner EL; Sevidal S; West MA; Clouser-Roche A; Freiwald S; Fenner K; Ullah M; Lee CA; Smith BJ
Drug Metab Dispos; 2013 Aug; 41(8):1575-83. PubMed ID: 23729661
[TBL] [Abstract][Full Text] [Related]
16. High-activity p-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells.
Karlsson JE; Heddle C; Rozkov A; Rotticci-Mulder J; Tuvesson O; Hilgendorf C; Andersson TB
Drug Metab Dispos; 2010 Apr; 38(4):705-14. PubMed ID: 20071452
[TBL] [Abstract][Full Text] [Related]
17. Efflux transporter breast cancer resistance protein dominantly expresses on the membrane of red blood cells, hinders partitioning of its substrates into the cells, and alters drug-drug interaction profiles.
Shi P; Liao M; Chuang BC; Griffin R; Shi J; Hyer M; Fallon JK; Smith PC; Li C; Xia CQ
Xenobiotica; 2018 Nov; 48(11):1173-1183. PubMed ID: 29098941
[TBL] [Abstract][Full Text] [Related]
18. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2.
Mease K; Sane R; Podila L; Taub ME
J Pharm Sci; 2012 May; 101(5):1888-97. PubMed ID: 22359351
[TBL] [Abstract][Full Text] [Related]
19. Role of intestinal efflux transporters in the intestinal absorption of methotrexate in rats.
Yokooji T; Murakami T; Yumoto R; Nagai J; Takano M
J Pharm Pharmacol; 2007 Sep; 59(9):1263-70. PubMed ID: 17883898
[TBL] [Abstract][Full Text] [Related]
20. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2).
Shen H; Lee FY; Gan J
J Pharmacol Exp Ther; 2011 May; 337(2):423-32. PubMed ID: 21262849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]